Eli Lilly structures Zepbound pricing at $349 monthly for starter doses and $499 monthly for standard doses
The comparison matters for practical reasons
Marked steatosis of microvesicles and macrovesicles in the liver, dilated sinusoids, and focal liver necrosis were observed
Some recent studies have indicated that semaglutide also acts on the brain, suggesting its potential usefulness in the treatment of various diseases, including neurodegenerative diseases such as Alzheimers and Parkinsons diseases [65]

Side-by-Side Comparison Feature Structure Melanotan 2 Cyclic 7-amino acid peptide Afamelanotide (MT-I) Linear 13-amino acid peptide PT-141 (Bremelanotide) Cyclic 7-amino acid derivative Feature Receptor focus Melanotan 2 MC1R + MC3R + MC4R + MC5R (non-selective) Afamelanotide (MT-I) MC1R-preferring PT-141 (Bremelanotide) MC3R/MC4R-preferring Feature Plasma half-life Melanotan 2 ~1-2 hours Afamelanotide (MT-I) ~0.8-1.7 hours PT-141 (Bremelanotide) ~2.7 hours Feature Main effect Melanotan 2 Tanning + sexual + appetite changes Afamelanotide (MT-I) Tanning and photoprotection PT-141 (Bremelanotide) Sexual arousal and desire Feature Tanning strength Melanotan 2 Strong Afamelanotide (MT-I) Strong PT-141 (Bremelanotide) Minimal Feature Sexual effect Melanotan 2 Strong in ED studies Afamelanotide (MT-I) Not primary PT-141 (Bremelanotide) Primary use case Feature Dosing Melanotan 2 Daily loading, then 1-2x weekly Afamelanotide (MT-I) Subcutaneous implant PT-141 (Bremelanotide) On-demand, max 1 per 24 hours Feature FDA status Melanotan 2 Not approved Afamelanotide (MT-I) Approved (Scenesse) for EPP PT-141 (Bremelanotide) Approved (Vyleesi) for low female sexual desire Feature Nausea burden Melanotan 2 High and dose-limiting Afamelanotide (MT-I) Lower in selective use PT-141 (Bremelanotide) Common, listed on label These three compounds share melanocortin ancestry, but they are not interchangeable

However, it was further noted that these savings are far outweighed by the $6,540 average annual drug cost for GLP1 therapy, making the shortterm return on investment (ROI) negative for most employers